

No. _____

In the
Supreme Court of the United States

NOVARTIS PHARMACEUTICALS CORP.,
Applicant,

v.

SECRETARY UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES;
ADMINISTRATOR CENTERS FOR MEDICARE & MEDICAID SERVICES;
UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES; CENTERS FOR
MEDICARE & MEDICAID SERVICES; SECRETARY UNITED STATES DEPARTMENT OF
TREASURY; UNITED STATES DEPARTMENT OF TREASURY; COMMISSIONER OF
INTERNAL REVENUE; INTERNAL REVENUE SERVICE,
Respondents.

**APPLICATION DIRECTED TO THE HONORABLE SAMUEL A. ALITO, JR.
FOR AN EXTENSION OF TIME WITHIN WHICH TO FILE A PETITION
FOR A WRIT OF CERTIORARI TO THE UNITED STATES COURT
OF APPEALS FOR THE THIRD CIRCUIT**

GREGORY G. GARRE
Counsel of Record
LATHAM & WATKINS LLP
555 Eleventh Street, NW
Suite 1000
Washington, DC 20004
(202) 637-2207
gregory.garre@lw.com

Counsel for Applicant
Novartis Pharmaceuticals Corp.

November 14, 2025

RULE 29.6 STATEMENT

Pursuant to Rule 29.6 of the Rules of this Court, Applicant Novartis Pharmaceuticals Corp. states that it is a direct, wholly owned subsidiary of Novartis Finance Corporation, a New York corporation; and Novartis Pharmaceuticals Corporation is an indirect, wholly owned subsidiary of Novartis AG, a Swiss company, and that no publicly held corporation owns 10% or more of its stock.

TO THE HONORABLE SAMUEL A. ALITO, JR., JUSTICE OF THE SUPREME COURT OF THE UNITED STATES AND CIRCUIT JUSTICE FOR THE THIRD CIRCUIT:

Pursuant to 28 U.S.C. § 2101(c) and Supreme Court Rules 13.5, 22, and 30.2, Applicant Novartis Pharmaceuticals Corp. (“Novartis”) respectfully requests a 60-day extension of time, to and including February 9, 2026, within which to file a petition for a writ of certiorari to review the judgment of the United States Court of Appeals for the Third Circuit in this case. The Third Circuit entered its judgment on September 11, 2025, App. A (“Op.”). Without an extension, the time for filing a petition for a writ of certiorari will expire on December 10, 2025. Jurisdiction to review the judgment of the Third Circuit in this case will be invoked under 28 U.S.C. § 1254(1).

1. This case raises constitutional questions of exceptional importance concerning an unprecedented effort by the government to requisition valuable drugs from manufacturers at prices well below market value, under threat of ruinous penalties. In 2022, Congress created the Drug Price Negotiation Program (the “Program”) as part of the Inflation Reduction Act. The Program threatens manufacturers with enterprise-destroying fines unless they “agree[]” to sell their products at highly discounted, government-dictated prices while publicly endorsing those prices as “fair prices” arrived at via “negotiation[s].” *See* 42 U.S.C. § 1320f *et seq.* For Novartis, that penalty would swiftly escalate to *\$93.1 billion each year*. Although branded as a “tax,” the Congressional Budget Office has estimated this “tax” would, in fact, raise zero revenue. Rather, in the words of the statute itself, it

is designed to force manufacturers' "[c]ompliance" with the Program's requirements. 26 U.S.C. § 5000D.

2. Novartis, which manufactures a drug that has been selected for inclusion in this regime, challenged the Program as imposing grossly disproportionate fines in violation of the Eighth Amendment, effectuating a *per se* taking of private property in violation of the Fifth Amendment, and compelling it to express the government's disputed messages about drug pricing in violation of the First Amendment.

3. The district court rejected all three challenges, and a panel of the Third Circuit affirmed. With respect to Novartis's Eighth Amendment claim, the panel held that the Tax Anti-Injunction Act—which prohibits suits “for the purpose of restraining the assessment or collection of any tax,” 26 U.S.C. § 7421(a)—deprived it of jurisdiction simply because Congress chose to label the penalty a “tax”—even though the statute is deliberately crafted such that *no* tax will ever be assessed or collected. *See* Op. 16-21. The panel further declined to apply the *Williams Packing* exception to the Anti-Injunction Act because, in its view, it was not “clear” Novartis would prevail on the merits because “[t]he Supreme Court has reserved the question of whether the Excessive Fines Clause applies to civil penalties imposed without any connection to criminal conduct.” *Id.* at 20-21.

On Novartis's First and Fifth Amendment claims, the panel relied on a decision it had issued one week earlier in *Bristol Myers Squibb Co. v. Secretary, United States Department of Health & Human Services* (“BMS”), 155 F.4th 245 (3d Cir. 2025),

rejecting parallel challenges to the Program because participation in Medicare—and thus the Program—is “voluntary.” *See* Op. 21-22.

That premise drew serious criticism from Judge Hardiman. In his dissenting opinion in *BMS*, Judge Hardiman explained that the Program is “voluntary” in name only because manufacturers cannot opt out without incurring “enterprise-crippling” penalties. 155 F.4th at 269, 273-81. Under that understanding, Judge Hardiman concluded that the Program effects a physical taking by “forc[ing] [manufacturers] to turn over physical doses of their drugs to Medicare beneficiaries.” *Id.* at 281. He likewise would have sustained the manufacturers’ compelled-speech challenges because the Program forces manufacturers to state in writing that the price set by CMS is not only the agreed-upon product of a negotiation, but also the “maximum fair price”—assertions the manufacturers vigorously dispute. *Id.* at 282-87. Judge Hardiman emphasized that the questions presented in these challenges are “of great importance to consumers of pharmaceutical drugs, the companies that provide them, and the public at large.” *Id.* at 289.

4. There is good cause to grant Novartis a 60-day extension of time within which to file a petition for a writ of certiorari in this case.

First, other courts—including the Fifth Circuit—are currently considering the constitutionality of the same Program. An extension would allow Novartis to evaluate and address developments in other cases challenging the Program, while promoting this Court’s ability to consider this case together with others that present similar constitutional challenges to the Program. For example, the Fifth Circuit

recently held oral argument in *National Infusion Center Association v. Kennedy*, No. 25-50661, an expedited appeal which presents similar constitutional challenges to the Program. Extending the deadline in this case may thus allow Novartis to address the decision in that case, and provide the Court with the benefit of an additional appellate decision in considering whether to grant certiorari in this case.

Second, undersigned counsel will be heavily engaged with other matters over the coming weeks, including: an oral argument before the Delaware Supreme Court on December 3, 2025, in *ITG Brands, LLC v. Reynolds American Inc.*, No. 204,2025; a merits brief due in this Court on December 12, 2025, in *Keathley v. Buddy Ayers Construction, Inc.*, No. 25-6; an oral argument before the Indiana Supreme Court on December 18, 2025, in *City of Fishers, Ind. v. Netflix, Inc.*, No. 24A-PL-01657; a merits response brief due in the Seventh Circuit on January 9, 2026, in *AbbVie Inc. v. Commissioner of Internal Revenue*, No. 25-2622; and an oral argument before the Second Circuit during the week of January 26, 2026, in *In re SVB Financial Group*, No. 25-00567. An extension of time would allow counsel sufficient time to fully examine the decision's consequences, narrow the issues for the Court's consideration, and adequately prepare and file a petition that addresses the important questions raised by this case in the most direct and efficient manner for the Court's consideration.


Third, the additional time will permit potential *amici curiae* to evaluate this case and consider how they might best assist the Court's review.

Finally, the extension requested would not work any meaningful prejudice on any party or prevent the Court from considering the petition before its summer recess.

Accordingly, Novartis respectfully requests a 60-day extension of time, to and including February 9, 2026, within which to file a petition for a writ of certiorari.

November 14, 2025

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Gregory G. Garre", is written over a horizontal line.

GREGORY G. GARRE

Counsel of Record

LATHAM & WATKINS LLP
555 Eleventh Street, NW
Suite 1000
Washington, DC 20004
(202) 637-2207
gregory.garre@lw.com

*Counsel for Applicant
Novartis Pharmaceuticals Corp.*

APPENDIX A

PRECEDENTIAL

UNITED STATES COURT OF APPEALS
FOR THE THIRD CIRCUIT

No. 24-2968

NOVARTIS PHARMACEUTICALS CORP.,
Appellant

v.

SECRETARY UNITED STATES DEPARTMENT OF
HEALTH AND HUMAN SERVICES; ADMINISTRATOR
CENTERS FOR MEDICARE & MEDICAID SERVICES;
UNITED STATES DEPARTMENT OF HEALTH AND
HUMAN SERVICES; CENTERS FOR MEDICARE &
MEDICAID SERVICES; SECRETARY UNITED STATES
DEPARTMENT OF THE TREASURY; UNITED STATES
DEPARTMENT OF THE TREASURY; COMMISSIONER
INTERNAL REVENUE SERVICE; INTERNAL REVENUE
SERVICE

On Appeal from the United States District Court
for the District of New Jersey
(D.C. No. 3:23-cv-14221)
District Judge: Honorable Zahid N. Quraishi

Argued on April 8, 2025

Before: HARDIMAN, PHIPPS, and FREEMAN, *Circuit Judges.*

(Filed: September 11, 2025)

Samir Deger-Sen [Argued]
Nikita Kansra
Latham & Watkins
1271 Avenue of the Americas
New York, NY 10020

Cherish A. Drain
Christina R. Gay
Graham B. Haviland
Daniel Meron
Latham & Watkins
555 11th Street NW
Suite 1000
Washington, DC 20004

Counsel for Appellant

Eric J. Hamilton
Michael S. Raab
Catherine M. Padhi* [Argued]
Maxwell A. Baldi
Lindsey Powell
United States Department of Justice
Civil Division

* Catherine M. Padhi withdrew as counsel on July 11, 2025, prior to the issuance of this opinion.

Rooms 7237, 7712, 7513, and 7259
950 Pennsylvania Avenue NW
Washington, DC 20530

Sean R. Keveney
Lena Yueh
David L. Hoskins
Kenneth R. Whitley
Anant Kumar
United States Department of Health and Human Services
Office of the General Counsel
200 Independence Ave. S.W.
Washington, D.C. 20201

Counsel for Appellees

Michael D. Lieberman
Rucha Desai
Fairmark Partners
400 7th Street NW
Suite 304
Washington, DC 20004

*Counsel for Amicus Curiae Patients for Affordable
Drugs in Support of Appellees*

Robin F. Thurston
Democracy Forward Foundation
P.O. Box 34553
Washington, DC 20043

*Counsel for Amici Curiae American Public Health
Association, American College of Physicians, Society of*

*General Internal Medicine, American Geriatrics
Society, and American Society of Hematology in
Support of Appellees*

Nandan M. Joshi
Allison M. Zieve
Wendy Liu
Public Citizen Litigation Group
1600 20th Street NW
Washington, DC 20009

Andrew M. Milz
Jody T. López-Jacobs
Flitter Milz
1814 E Route 70
Suite 350
Cherry Hill, NJ 08003

*Counsel for Amici Curiae Public Citizen, Doctors for
America, Families USA, and Protect Our Care in
Support of Appellees*

Brianne J. Gorod
Elizabeth B. Wydra
Nina G. Henry
Constitutional Accountability Center
1200 18th Street NW
Suite 501
Washington, DC 20036

*Counsel for Amicus Curiae Constitutional
Accountability Center in Support of Appellees*

Julie Nepveu
Kelly Bagby
William Alvarado Rivera
AARP Foundation Litigation
601 E Street NW
Washington, DC 20049

*Counsel for Amici Curiae AARP, AARP Foundation,
Justice in Aging, Center for Medicare Advocacy,
Medicare Rights Center in Support of Appellees*

Hannah W. Brennan
Claudia Morera
Rebekah Glickman-Simon
Hagens Berman Sobol Shapiro
One Faneuil Hall Square
5th Floor
Boston, MA 02109

*Counsel for Amici Curiae Law Professors and Scholars
in Support of Appellees*

Alyssa H. Card
Margaret Dotzel
William B. Schultz
Zuckerman Spaeder
2100 L Street NW
Suite 400
Washington, DC 20037

*Counsel for Amici Curiae Stuart Altman, Robert
Berenson, Donald Berwick, David Blumenthal, Francis*

*J. Crosson, Paul Ginsburg, Marilyn Moon, and Bruce
Vladeck in Support of Appellees*

Flavio L. Komuves
Weissman & Mintz
220 Davidson Avenue
Suite 410
Somerset, NJ 08873

*Counsel for Amicus Curiae Abrams Institute for
Freedom of Expression in Support of Appellees*

Hannah W. Brennan
Hagens Berman Sobol Shapiro
One Faneuil Hall Square
5th Floor
Boston, MA 02109

*Counsel for Amici Curiae Center for American
Progress, Century Foundation, and UnidosUs Action
Fund in Support of Appellees*

OPINION OF THE COURT

HARDIMAN, *Circuit Judge*.

Novartis appeals a summary judgment rejecting its constitutional challenge to portions of the Inflation Reduction Act of 2022 (the Act). As relevant here, the Act was passed to

slow the rapid growth of federal outlays for prescription drugs. To that end, the Act established what it called the “Drug Price Negotiation Program” (the Program). The Program directs the Department of Health and Human Services (HHS)—through the Centers for Medicare and Medicaid Services (CMS)—to “negotiate” prices with drug manufacturers. *See* 42 U.S.C. § 1320f(a)(3).

Novartis contends that the Program (1) threatens it with an excessive fine in violation of the Eighth Amendment; (2) takes its property without just compensation in violation of the Fifth Amendment; and (3) compels it to speak in violation of the First Amendment. Perceiving no error in the District Court’s judgment, we will affirm.

I

“Medicare is a federal medical insurance program for people ages sixty-five and older and for younger people with certain disabilities.” *AstraZeneca Pharms. LP v. Sec’y U.S. Dep’t of HHS*, 137 F.4th 116, 119 (3d Cir. 2025). “Medicaid is a joint federal and state program that provides medical coverage for people with limited incomes.” *Id.*

The Program at issue in this appeal targets Medicare Parts B and D. *See id.* at 120. Part B is a “supplemental insurance program that covers outpatient care, including certain prescription drugs that are typically administered by a physician.” *Id.* Part D is a “prescription drug benefit program that subsidizes the cost of prescription drugs and prescription

drug insurance premiums for Medicare enrollees.” *Id.* (citation omitted).

Part D is administered through prescription drug plans operated by private insurers called “sponsors.” *Id.* Sponsors bid to be accepted into Medicare Part D and contract with CMS for reimbursement. *See* 42 U.S.C. §§ 1395w-111–1395w-112; *see also* 42 C.F.R. § 423.301 *et seq.* (setting forth rules for reimbursing sponsors). Sponsors, in turn, work with subcontractors, such as pharmacy benefit managers, who process claims and perform other administrative tasks. *See AstraZeneca*, 137 F.4th at 120. Those subcontractors then work with the pharmacies that dispense prescription drugs to Medicare Part D beneficiaries. *See id.*

When Congress enacted Part D in 2003, it prohibited CMS from “interfer[ing] with the negotiations between drug manufacturers and pharmacies and . . . sponsors” and from “institut[ing] a price structure for the reimbursement of covered part D drugs.” 42 U.S.C. § 1395w-111(i)(1), (3) (2003). Almost twenty years later, however, the Act created an exception, directing CMS to “negotiate . . . maximum fair prices” for certain drugs, *id.* § 1320f(a)(3), subject to price ceilings derived from a benchmark market-based price, *id.* § 1320f-3(c). A “selected drug’s ‘maximum fair price’ applies beginning in a given drug-pricing period (a period of one calendar year), the first of which is 2026, until the drug is no longer eligible for negotiation or the price is renegotiated.” *AstraZeneca*, 137 F.4th at 120 (citing 42 U.S.C. §§ 1320f(b)(1)–(2), 1320f-1(c), 1320f-3(f)).

The Act required CMS to select ten drugs for the first drug-pricing period. *See* 42 U.S.C. §§ 1320f(d) and 1320f-1(a). As the Program ramps up, CMS must select 15 more

drugs per year for the 2027 and 2028 drug-pricing periods and up to 20 more drugs per year for 2029 and subsequent drug-pricing periods. *See id.* § 1320f–1(a). The selected drugs must have accounted for the largest costs for Medicare that prior year. *See id.* § 1320f–1(b)(1)(A). A selected drug remains in the Program until CMS determines that a generic or biosimilar version of the drug has been approved and is being marketed. *See id.* §§ 1320f–1(c)(1), 1320f–2(b).

When CMS selects a drug for the Program, the drug’s manufacturer must “enter into [an] agreement[]” to “negotiate . . . a maximum fair price for such selected drug.” *Id.* § 1320f–2(a)(1). For the first round of selections, the manufacturer of a selected drug had until October 1, 2023, to enter an agreement obligating it to “negotiate” a “maximum fair price” for the drug. *See id.* § 1320f(b)(4), (d)(2)(A).

CMS drafted a template agreement that manufacturers must sign to comply with this “negotiation” obligation. *See CMS, Medicare Drug Price Negotiation Program Agreement*, <https://perma.cc/ZC3E-XCQ5> (last visited June 20, 2025), at 1–6 (hereinafter Agreement). The Agreement states that “CMS and the Manufacturer agree” that they “shall negotiate to determine (and, by not later than the last date of [the negotiation] period, agree to) a maximum fair price for the Selected Drug.” Agreement at 2; *see also* 42 U.S.C. § 1320f–2(a)(1).

Once a manufacturer signs the Agreement, the agency makes a “written initial offer.” 42 U.S.C. § 1320f–3(b)(2)(B). The agency must issue the offer by a statutory deadline, propose a “maximum fair price,” and include a concise justification for the offer based on statutory criteria. *Id.* The manufacturer then has 30 days to accept the offer or make a

counteroffer. *See id.* § 1320f–3(b)(2)(C). CMS must respond in writing to any counteroffer. *See id.* § 1320f–3(b)(2)(D).

Negotiations for the first round of selections were to end by August 1, 2024. *See id.* §§ 1320f(b)(4), (d)(2)(B), (d)(5)(C), 1320f–3(b)(2)(E). Before that deadline, the manufacturer had to “respond in writing” to the agency “by either accepting or rejecting the final offer.” CMS, *Medicare Drug Price Negotiation Program: Revised Guidance, Implementation of Sections 1191-1198 of the Social Security Act for Initial Price Applicability Year 2026*, at 158 (June 30, 2023) (2023 Revised Guidance), <https://perma.cc/AV2Z-4F9U>. The agency and manufacturers must follow a similar process for future drug-pricing periods, except the deadlines will be set for different times of the calendar year. *See id.* § 1320f–3(b)(2).

The Act sets a price ceiling for selected drugs that CMS cannot exceed when it makes a manufacturer an offer. *Id.* § 1320f–3(c)(1)(A). And it requires CMS to “aim[] to achieve the lowest maximum fair price for each selected drug,” *id.* § 1320f–3(b)(1), not to exceed 75 percent of a benchmark based on private market prices for the drug, *id.* § 1320f–3(b)(2)(F), (c)(1)(C), (c)(3). Lower price ceilings (65 or 40 percent) apply to drugs that have been approved for a longer time (at least 12 or 16 years, respectively). *Id.* There is no price floor, but the offer must be “justified” based on certain factors identified in the statute. *Id.* § 1320f–3(b)(2)(B), (b)(2)(C)(ii), (e). The Act forecloses judicial review of, among other things, CMS’s pricing decisions, selection of drugs, and determinations about which drugs are eligible for selection. *See id.* § 1320f–7.

In addition to the Agreement, CMS created a template addendum a manufacturer must sign to formalize a price for its

selected drug. *See* Agreement at 7–9. The addendum states that “[t]he parties agree to a price of [\$],” which the addendum’s recitals note is referred to as a “maximum fair price” in the statute. Agreement at 7. Once the process is completed, the Act directs CMS to publish the “maximum fair price” that it “negotiated with the manufacturer” and its “explanation” for the price. 42 U.S.C. § 1320f–4(a).

Once signed, the Agreement obliges the manufacturer to “provide access to such price” for its selected drug to Medicare beneficiaries beginning in 2026. Agreement at 2; 42 U.S.C. § 1320f–2(a)(1). Failure to do so triggers a civil monetary penalty of ten times the difference between the price charged and the maximum fair price for every unit sold. 42 U.S.C. § 1320f–6(a). An offending manufacturer also will be subject to a civil monetary penalty of \$1,000,000 for each day the Agreement was violated. *Id.* § 1320f–6(c).

After CMS includes a drug in the Program, the manufacturer can walk away and choose not to do business with the government. But if a manufacturer continues to fully participate in Medicare and Medicaid without signing an agreement under the Program, it must pay a daily excise tax that begins at 185.71 percent and rises to 1,900 percent of the selected drug’s total daily revenues from all domestic sales. *See* 26 U.S.C. § 5000D.

We have held that the Act provides an escape hatch for a company that declines to participate in the Program. A manufacturer can cause the excise tax to be “[s]uspen[ded]” by terminating its extant Medicare and Medicaid agreements (under the Medicare Coverage Gap Discount Program, the Manufacturer Discount Program, and the Medicaid Drug Rebate Program). 26 U.S.C. § 5000D(c); *Bristol Myers Squibb*

v. Sec’y U.S. Dep’t of HHS, ___ F.4th ___, ___, 2025 WL 2537005, at *3 (3d Cir. Sept. 4, 2025).

Novartis claims that this exit option is illusory, but this Court recently held otherwise. *See Bristol Myers Squibb*, ___ F.4th at ___, 2025 WL 2537005, at *5. CMS may terminate a manufacturer’s extant Medicare agreements under the Coverage Gap Discount and Manufacturer Discount Programs for “good cause” effective upon 30 days’ notice. 42 U.S.C. §§ 1395w-114a(b)(4)(B)(i), 1395w-114c(b)(4)(B)(i). Relying on that authority, CMS promised to offer manufacturers a 30-day exit from the Coverage Gap Discount and Manufacturer Discount Programs upon request, which it said would enable a manufacturer to avoid excise tax liability. 2023 Revised Guidance at 33–34, 120–21. We have held that CMS has statutory authority to do so and that participation in the Program is therefore voluntary. *See Bristol Myers Squibb*, ___ F.4th at ___, 2025 WL 2537005, at *8.

II

In the first round of selections, CMS selected Novartis’s drug Entresto for inclusion in the Program. Novartis signed an Agreement to participate in the Program by the October 1, 2023, deadline and an addendum setting a “maximum fair price” by the August 1, 2024, deadline.

In September 2023, Novartis sued HHS and its Secretary along with CMS and its Administrator. It alleged that the Program violated the Eighth Amendment’s Excessive Fines Clause, the Fifth Amendment’s Takings Clause, and the First Amendment’s Free Speech Clause.

The parties filed cross-motions for summary judgment.

The District Court denied Novartis’s motion, granted the Government’s motion, and entered judgment in favor of the Government. *See Novartis Pharms. Corp. v. Becerra*, 2024 WL 4524357, at *1 (D.N.J. Oct. 18, 2024). It rejected Novartis’s Fifth and First Amendment claims by reasoning, among other things, that participation in the Program is voluntary and that the Program primarily regulates conduct. As for the Eighth Amendment argument, the Court concluded that the Tax Anti-Injunction Act and Declaratory Judgment Act divested it of jurisdiction. Novartis appealed.¹

III

A

Novartis argues that the Act’s excise tax threatens it with an excessive fine in violation of the Eighth Amendment. But before we can reach that contention, we must first decide (1) whether Novartis has standing to raise it and (2) whether

¹ The District Court had jurisdiction under 28 U.S.C. § 1331, and we have jurisdiction under 28 U.S.C. § 1291. Our review of the District Court’s summary judgment is *de novo*. *See Canada v. Samuel Grossi & Sons, Inc.*, 49 F.4th 340, 345 (3d Cir. 2022). Summary judgment is appropriate “if the movant shows that there is no genuine dispute as to any material fact and the movant is entitled to judgment as a matter of law.” Fed. R. Civ. P. 56(a).

our review of the claim is barred by the Tax Anti-Injunction Act and the Declaratory Judgment Act.

1

Novartis has standing to bring its Eighth Amendment claim. To establish standing, Novartis must show that it “has suffered an injury in fact that is fairly traceable to the defendant’s allegedly unlawful conduct and likely to be redressed by the requested relief.” *Haaland v. Brackeen*, 599 U.S. 255, 291–92 (2023) (citation modified).

The Government focuses on redressability. It argues that Novartis’s requested relief is unlikely to redress its injuries because the entity it sued, CMS, is not responsible for them. Novartis should have sued the IRS or the Treasury, the Government explains, because its alleged injury stems from a tax that is assessed, collected, and enforced by those entities. Because “the IRS can collect on that tax regardless of anything CMS does,” the Government argues that an injunction against CMS will not remedy Novartis’s injury. Gov’t Br. 34. We disagree.

CMS is, at least in part, responsible for Novartis’s alleged injuries. The Act obliges CMS to collect the information necessary for determining whether a manufacturer is subject to the excise tax. And it instructs CMS to “shar[e] with the Secretary of the Treasury . . . such information as is necessary to determine the tax imposed by section 5000D.” 42 U.S.C. § 1320f–5(a)(6). That “includ[es] the application of such tax to a manufacturer, producer, or importer or the

determination of any date described in section 5000D(c)(1).”

Id. It also includes:

(A) the date on which the Secretary receives notification of any termination of an agreement under the Medicare coverage gap discount program . . . and the date on which any subsequent agreement under such program is entered into;

(B) the date on which the Secretary receives notification of any termination of an agreement under the manufacturer discount program . . . and the date on which any subsequent agreement under such program is entered into; and

(C) the date on which the Secretary receives notification of any termination of a rebate agreement described in section 1396r-8(b) of this title and the date on which any subsequent rebate agreement described in such section is entered into.

Id. This information is necessary to determine whether a manufacturer is subject to the excise tax. *See* 26 U.S.C. § 5000D(b), (c). In guidance, CMS has also stated that “[m]anufacturers of selected drugs without an Agreement in place are referred to IRS.” App. 354. So contrary to the Government’s assertion, CMS does contribute to Novartis’s alleged injury.

That injury “likely would be redressed” by injunctive and declaratory relief issued against CMS. *FDA v. All. for Hippocratic Med.*, 602 U.S. 367, 380 (2024). Novartis’s

requested injunctive and declaratory relief would prohibit CMS from following its statutory obligation to provide the information the IRS would need to calculate excise tax liability. So the relief Novartis requested would reduce its “risk of [future] harm to some extent.” *Massachusetts v. EPA*, 549 U.S. 497, 526 (2007); *see also Diamond Alternative Energy, LLC v. EPA*, 145 S. Ct. 2121, 2135 (2025).

After Novartis filed its complaint, the IRS issued regulations requiring manufacturers to self-report excise tax liability. Excise Tax on Designated Drugs; Procedural Requirements, 89 Fed. Reg. 55507 (July 5, 2024). To avoid any doubt about redressability, we will add the Treasury and IRS as parties. Fed. R. Civ. P. 21; *Balgowan v. State of N.J.*, 115 F.3d 214, 216–17 (3d Cir. 1997). We exercise our discretion to do so because the IRS issued its regulations well into the litigation of this case and the circumstances indicate that the joined parties and their counsel have been on notice of Novartis’s claim. *See Silbaugh v. Chao*, 942 F.3d 911, 913–14 (9th Cir. 2019); *see also Swan v. Clinton*, 100 F.3d 973, 980 n.3 (D.C. Cir. 1996).

2

Although Novartis has standing to bring its Eighth Amendment challenge, the Tax Anti-Injunction Act and the Declaratory Judgment Act preclude our review. The Tax Anti-Injunction Act provides that, with certain enumerated exceptions, “no suit for the purpose of restraining the assessment or collection of any tax shall be maintained in any

court by any person.” 26 U.S.C. § 7421(a).² Similarly, the Declaratory Judgment Act, with certain exceptions, precludes courts from issuing declaratory judgments “with respect to Federal taxes.” 28 U.S.C. § 2201(a). “There is no dispute . . . that the federal tax exception to the Declaratory Judgment Act is at least as broad as the Anti-Injunction Act.” *Bob Jones Univ. v. Simon*, 416 U.S. 725, 732 n.7 (1974).

A claim is barred by the Anti-Injunction Act if (1) the exaction at issue is a “tax” and (2) the purpose of the claim is to “restrain[] the assessment or collection of [that] tax.” 26 U.S.C. § 7421(a). Novartis’s suit satisfies these preconditions.

First, the excise tax is a “tax” within the meaning of the Anti-Injunction Act. Congress has wide latitude to label an exaction a “tax.” See *Nat’l Fed’n of Indep. Bus. v. Sebelius (NFIB)*, 567 U.S. 519, 544 (2012). That is because the Anti-Injunction Act is a “creature[] of Congress’s own creation.” *Id.* Because of this discretion, the Supreme Court has applied the Anti-Injunction Act bar to exactions Congress labeled as taxes even where that label was inaccurate for constitutional purposes. Compare *Bailey v. George*, 259 U.S. 16, 20 (1922) (holding that a suit seeking to enjoin a child labor tax was barred), with *Child Labor Tax Case (Bailey v. Drexel Furniture Co.)*, 259 U.S. 20, 36–37, 44 (1922) (striking down a child labor tax because it exceeded Congress’s taxing power). How the Inflation Reduction Act and the Anti-Injunction Act “relate to each other is up to Congress, and the best evidence of

² We refer to 26 U.S.C. § 7421(a) as the Tax Anti-Injunction Act to distinguish it from an unrelated statute called the Anti-Injunction Act: 28 U.S.C. § 2283, which restricts a federal court’s authority to enjoin state court proceedings, subject to certain exceptions.

Congress’s intent is the statutory text.” *NFIB*, 567 U.S. at 544. Because Congress labeled the exaction a “tax,” it is a tax within the meaning of the Anti-Injunction Act. 26 U.S.C. § 5000D(a), (c), (f)(2).

Second, the purpose of Novartis’s Eighth Amendment claim is to “restrain[] the assessment or collection of [the] tax.” 26 U.S.C. § 7421(a). To determine the purpose of a suit, “we inquire not into a taxpayer’s subjective motive, but into the action’s objective aim—essentially, the relief the suit requests.” *CIC Servs., LLC v. IRS*, 593 U.S. 209, 217 (2021).

The Supreme Court’s decision in *CIC Services* is illustrative. There, a material advisor to taxpayers brought a pre-enforcement challenge to an IRS notice imposing a new self-reporting requirement on parties that engage in certain potentially taxable transactions. *Id.* at 213–15. If a taxpayer or advisor failed to comply with the notice, he could be subject to civil monetary penalties (deemed by Congress to be “taxes” for purposes of the Anti-Injunction Act) and criminal prosecution. *Id.* at 214. The advisor asked the court to set aside the notice, enjoin its enforcement, and declare it unlawful. *Id.* at 215.

The Court held that the advisor’s suit was not barred by the Anti-Injunction Act because it targeted the notice, not the taxes that backed the notice. *Id.* at 223. Three aspects of the regulatory scheme supported the Court’s conclusion: (1) the notice imposed affirmative reporting obligations, which inflicted costs separate and apart from the tax penalty for noncompliance; (2) the statutory tax penalty for noncompliance was several steps removed from the notice’s reporting rule; and (3) noncompliance could be punished by

separate criminal penalties, which “practically necessitate[d] a pre-enforcement, rather than a refund, suit.” *Id.* at 220–22.

This case is different. Unlike the advisor in *CIC Services*, Novartis sought declaratory and injunctive relief that would run against the assessment and collection of the excise tax *itself*. True, it did not specifically request an injunction with respect to the tax. But it asked the District Court to “[d]eclare that the Program’s ‘excise tax’ violates the Excessive Fines Clause.” App. 86. It also asked the Court to “[d]eclare void any agreement that Novartis may be unconstitutionally coerced into entering before this case is adjudicated” and to “[e]njoin Defendants from forcing Novartis to sign an initial ‘manufacturer agreement’ or to ‘agree’ to prices set by the Program.” *Id.* By seeking to enjoin CMS from “forcing” it to participate in the Program, Novartis effectively sought to enjoin CMS from collecting information about excise tax liability and sharing it with the IRS for collection.

Novartis disputes this characterization of its complaint. It argues that it seeks “invalidation of” and “an injunction against the enforcement of” the “entire statute” on Eighth Amendment grounds, “not just the fine.” Reply Br. 2, 15. But at bottom, its claim is that the excise tax violates the Excessive Fines Clause—not that some other part of the statute does so. That is the inverse of *CIC Services*, where the plaintiff targeted the IRS notice (rather than the taxes for noncompliance). 593 U.S. at 214–15, 219.

Novartis insists that its suit cannot have the purpose of restraining the assessment or collection of the excise tax when Congress expects to raise no revenue from it. This purposive argument suggests that because the government’s ability to collect revenue is not in danger, Congress could not possibly

have intended for the Anti-Injunction Act to bar this suit. We decline Novartis’s invitation to elevate the statute’s supposed purpose over its plain text. The Supreme Court has been clear that the Anti-Injunction Act “draws no distinction between regulatory and revenue-raising tax rules.” *CIC Servs.*, 593 U.S. at 225. And Novartis points to no case in which the Court has drawn a distinction between regulatory taxes expected to raise revenue and those that are not.

Novartis finally argues that its suit fits within a narrow carveout to the Anti-Injunction Act: the *Williams Packing* exception. A plaintiff may obtain an injunction under that exception if it (1) will otherwise suffer “irreparable injury” and (2) can demonstrate “certainty of success on the merits.” *Bob Jones*, 416 U.S. at 737 (citing *Enochs v. Williams Packing & Nav. Co.*, 370 U.S. 1, 6–7 (1962)).

We need not consider whether Novartis would suffer irreparable injury because it cannot demonstrate “certainty of success on the merits.” *Id.* Novartis can evade the Anti-Injunction Act bar only if it is “apparent that, under the most liberal view of the law and the facts,” its Eighth Amendment claim will succeed. *Williams Packing*, 370 U.S. at 7. The Supreme Court has warned that this deferential standard stems from the Anti-Injunction Act’s “objective of . . . protect[ing] . . . the collector from litigation pending a suit for refund.” *Id.* at 8. “[T]o permit even the maintenance of a suit in which an injunction could issue only after the taxpayer’s nonliability had been conclusively established might in every practical sense operate to suspend collection of the taxes until the litigation is ended.” *Id.* (citation modified).

The Supreme Court has reserved the question of whether the Excessive Fines Clause applies to civil penalties

imposed without any connection to criminal conduct. *See Browning-Ferris Indus. of Vermont, Inc. v. Kelco Disposal, Inc.*, 492 U.S. 257, 262–64 (1989). So it was far from certain that Novartis would win on the merits of its claim at the time the District Court considered its Eighth Amendment claim.

As for the Declaratory Judgment Act, Novartis plainly sought declaratory relief “with respect to Federal taxes.” 28 U.S.C. § 2201(a); App. 86 (asking for the District Court to “[d]eclare that the Program’s ‘excise tax’ violates the Excessive Fines Clause”). So the Declaratory Judgment Act bars the District Court from offering Novartis declaratory relief on its claim. *Bob Jones*, 416 U.S. at 732 n.7; *Rivero v. Fid. Invs., Inc.*, 1 F.4th 340, 344–46 (5th Cir. 2021). Accordingly, we cannot review Novartis’s Eighth Amendment claim.

B

We now consider Novartis’s claim that the Program takes its property without providing just compensation. We addressed this issue in *Bristol Myers Squibb*. *See* ___ F.4th at ___, 2025 WL 2537005, at *3–9. For the reasons we explained there, we hold that the Program does not violate the Takings Clause. *See* ___ F.4th at ___, 2025 WL 2537005, at *9. So we will affirm the District Court’s summary judgment on Novartis’s Fifth Amendment claim.

C

Finally, we turn to Novartis’s claim that the Program compels it to speak in violation of the First Amendment. We addressed this issue too in *Bristol Myers Squibb*. *See* ___ F.4th at ___, 2025 WL 2537005, at *10–15. For the reasons we explained there, we hold that the Program does not violate the

First Amendment. *See id.* at ____, 2025 WL 2537005, at *10. So we will affirm the District Court's summary judgment on this claim.

* * *

Novartis seeks an injunction and declaratory relief with respect to a federal tax on its Eighth Amendment claim, so we cannot review its claim on the merits. And its Fifth and First Amendment claims are foreclosed by our precedent. Accordingly, we will affirm the District Court's judgment.